Video

Dr. Ward on Considerations for Salvage Radiation Therapy in Prostate Cancer

Matthew C. Ward, MD, discusses considerations for salvage radiation therapy in prostate cancer.

Matthew C. Ward, MD, radiation oncologist, Levine Cancer Institute, Atrium Health, discusses considerations for salvage radiation therapy in prostate cancer.

In considering salvage radiation for a patient with prostate cancer, it is critical to look at the patient’s pathology report, margin status, disease stage, lymph node involvement, extent of node dissection, and final Gleason score, says Ward. In addition, prostate-specific antigen (PSA) levels can inform whether salvage radiation therapy should be indicated for a patient, Ward adds.

Patients with high PSA should receive an escalation in treatment, says Ward. However, each treatment decision requires a discussion with a patient to determine whether adding radiation therapy or androgen-deprivation therapy is optimal, Ward concludes.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD